IL4‐10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10

The objective of this study was to test the capacity of a newly developed fusion protein of interleukin 4 (IL‐4) and IL‐10 [IL4‐10 fusion protein (FP)] to shift multiple pro‐inflammatory pathways towards immune regulation, and to inhibit pro‐inflammatory activity in arthritis models. The effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Steen‐Louws, C., Hartgring, S. A. Y., Popov‐Celeketic, J., Lopes, A. P., de Smet, M. B. M., Eijkelkamp, N., Lafeber, F. P. J. G., Hack, C. E., van Roon, J. A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Editor's Choice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300648/
https://www.ncbi.nlm.nih.gov/pubmed/30307604
http://dx.doi.org/10.1111/cei.13224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300648/
https://www.ncbi.nlm.nih.gov/pubmed/30307604
http://dx.doi.org/10.1111/cei.13224

Ejemplares similares